ETHICS AND DIVERSITY

Justice, diversity, and research ethics review

It is time for institutional review boards and research ethics committees to address the ethics of inclusion

By David H. Strauss1,2, Sarah A. White1,3, Barbara E. Bierer1,3,4

The disproportionate impact of COVID-19 on certain populations, such as Black, Latinx, and Indigenous populations in the United States, has focused attention on inequalities in health and on the need to increase enrollment of racial and ethnic minorities and other underrepresented groups in biomedical research (1). Yet too often, in the United States and globally, participant enrollment in research has not reflected the demographic composition of the general population, those affected by the health conditions being studied, or those for whom the investigational product is intended (2), with racial and ethnic minorities and the young and the elderly, among others, being consistently underrepresented (3). Underlying causes for this underrepresentation have been described (4, 5), but change has been slow. Notwithstanding the roles of other stakeholders in addressing this issue, we maintain that the specific value of institutional review boards (IRBs) and research ethics committees (RECs) in promoting diversity has been underrecognized and their authority underutilized. Here, we substantiate the role of and outline practical steps for the IRB and REC (hereafter “IRB”) to help achieve greater diversity in clinical research.

The appropriate inclusion of diverse populations in clinical research is necessary if we are to understand how biological variability and social determinants of health contribute to disease prevalence, transmission, course, experience of illness, and treatment outcome. The inclusion of understudied and underserved groups informs clinical decision-making and health policy and can serve efforts to address mistrust of research and health care (6, 7). Responsibility to the goals of diversity lies with all stakeholders in the clinical research enterprise (6), and a commitment to diversity, individually and collaboratively, by research sponsors, funders, academic institutions, contract research organizations, study sites, investigators, and IRBs is necessary.

RESPECT, BENEFICENCE, JUSTICE

Most regulated clinical research undergoes obligate review and approval by an IRB. IRBs are charged with safeguarding the rights and well-being of human participants in accordance with the foundational tenets of respect for persons, beneficence, and justice, as described in the Belmont Report (8). An IRB’s ethical responsibilities with regard to diversity derive from these and other principles, guidelines, and standards (9, 10).

The discussion of justice in Belmont cites “moral requirements that there be fair procedures and outcomes in the selection of research subjects.” As Belmont and other codes of ethics evolved from a historical backdrop of abuse and injustice in research, “fair procedures” have been applied by IRBs largely (and, we believe, too narrowly) to ensure that subjects are not exploited and enrolled as a matter of convenience. The idea of justice within the Belmont Report also includes the notion of access to the benefits of research (i.e., knowledge gained); this has direct implications for populations that have been understudied, whether incidentally or systemically. Subject selection cannot be equitable, and the requirements of justice cannot be met, when there is de facto exclusion of understudied populations.

This notion of justice is supported by the World Health Organization’s International Ethical Guidelines for Health-related Research Involving Humans, Guideline 3, which states, “In cases where the underrepresentation of particular groups results in or perpetuates health disparities, equity may require special efforts to include members of those populations in research” (9), and by the World Medical Association Declaration of Helsinki, which states, “Groups that are underrepresented in medical research should be provided appropriate access to participation in research” (10). Therefore, consideration of diversity is essential to the question of fairness in subject selection and to IRB review.

Diversity in clinical research is responsive to the principle of beneficence, which places priority on the welfare of research participants and creates the obligation that research presents a favorable balance of benefit to risk, after risks and burdens have been minimized. In calling for “maximization of benefits” in the research, Belmont directs attention to both individual benefit and to the broader value of research to society. A clinical research enterprise that is not inclusive does not adequately address the health needs of a diverse society. Group differences in susceptibility to disease and in treatment outcome can only be identified when those groups are studied. It is the obligation of an IRB to maximize benefits through the inclusion of understudied groups in a manner that is consistent with the study aims and does not introduce unacceptable harm or burden.

Belmont describes two ethical convictions in relation to respect for persons, self-determination, and decision-making: the obligations to treat individuals as autonomous agents and to protect those with diminished autonomy. IRBs provide additional safeguards for research involving participants with compromised voluntariness (e.g., prisoners) or impaired comprehension. With regard to the inclusion of diverse populations, respect for persons demands efforts to foster informed and autonomous decision-making and, therefore, to address common barriers posed by age, language, culture, and educational disadvantage. Respect for persons requires the identification of opportunities and resources to engage understudied populations and to enhance awareness, access, and inclusion in research (4, 6). It also demands modification of those aspects of research and of consent that inadvertently limit the participation of understudied populations. For example, although inclusion of non-English speakers in a study may involve additional expenses of translation and/or interpreters, it strengthens the commitment to autonomy and justice.

The ethical positions presented above compel attention to inclusion of diverse populations in clinical research and define a specific duty for the IRB. In a 2019 survey (11), a majority of IRB chairs, IRB ad-

1Multi-Regional Clinical Trials Center of Brigham and Women’s Hospital and Harvard University, Cambridge, MA, USA. 2Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA. 3Brigham and Women’s Hospital, Boston, MA, USA. 4Harvard Medical School, Boston, MA, USA. Email: bbierer@bwh.harvard.edu
Inclusion and Protection

In the face of the persistent problem of underrepresentation in clinical research, institutions should establish policies and provide necessary resources at all institutional levels to ensure that reviewing IRBs fulfill this obligation. The specific approaches we outline here will serve to help incorporate the ethical oversight of diversity in IRB procedures, deliberations, and expectations (see the box).

An IRB has authority to require that a research protocol details study elements relevant to considerations of diversity. A description and justification by the investigator of the demographics of the intended study sample (e.g., by age, sex, race, ethnicity, social determinants of health) and a description of either the demographics of the condition or those using or intended to use the product in the general population permit the IRB to make an assessment of the appropriateness of the recruitment plan. When the makeup of the proposed sample deviates substantially from that of the demographics of the condition being studied in the general population or for whom the intervention is intended, and no valid scientific justification is offered, the IRB can require modification of the study to recruit a more representative sample. Such requirements are tailored to the nature and phase of the study, the study’s specific aims, and the study location, as discussed further below.

Note that inclusion of a demographically diverse study population does not imply that statistical conclusions regarding heterogeneity of treatment outcome will be possible, but it may allow directional assessments of efficacy and safety that can then be further investigated. Inclusion will, at a minimum, address the equitable selection of participants and the principle of justice in research.

Upon initial review of the study protocol, investigators should detail study inclusion and exclusion criteria, recruitment plans, and study conduct. The IRB can review and provide specific feedback to facilitate successful recruitment of specific populations, including language use, translation, placement of advertisements, and workforce characteristics. The IRB should ensure that all study materials adhere to health literacy principles and that user-testing is utilized where indicated. The IRB should also consider factors, such as excessive time commitment, restricted clinic hours, the costs of travel, and inadequate compensation, that have a foreseeable and negative impact on the enrollment of an appropriately representative sample.

IRBs should require investigators to detail study inclusion and exclusion criteria and, when not self-evident, to provide a rationale for exclusion. Review of eligibility criteria should ensure that understudied populations are not inadvertently or unnecessarily excluded and that criteria are only as restrictive as necessary for safety and to minimize harm. For example, the exclusion of older populations with a specific age criterion might be revised to exclude individuals with specific health concerns who would be at increased risk, regardless of age. When laboratory measures serve as the basis for eligibility criteria, they should be adapted to reflect known sex-, age-, race-, and other demographic differences.
or ancestry-specific normal values, when failure to do so would unnecessarily decrease eligibility of some individuals (14). IRBs should identify common practices that limit enrollment of immigrant or minority language speakers in multilingual communities, restrict the participation of women of child-bearing potential (when requiring appropriate contraception would suffice), and introduce bias in participant selection by using overly subjective criteria (such as “investigator discretion”).

In exercising the regulatory requirement for continuing oversight of ongoing research, the IRB should periodically review the demographic breakdown of the accrued sample by age, race, ethnicity, sex, and social determinants of health where applicable to the research. Along with these data, IRBs should require an explanation of any meaningful departures from the recruitment plan and request, review, and approve proposed corrective action when indicated.

“Equitable subject selection requires the balancing of inclusion and protection…”

The findings are generalizable, and whether an alternative recruitment strategy might yield a more diverse or less burdened, stigmatized, or disadvantaged population.

Flexible adapting requirements to specific study types will encourage dialogue between investigators and the IRB. When an investigator faces particular challenges in the recruitment and retention of specific populations, the IRB could offer guidance or consultation on protocol revision.

The IRB itself should be diverse in composition, with membership and input reflecting the demographic compositions of the communities and populations studied in the research it reviews through the use of ad hoc consultants and by appointing members with experience working with diverse communities. However, a recent study showed that 87% of IRB members and 91% of IRB chairs were white (11). A diverse IRB will be better attuned to the experience and needs of participants and better able to offer input from the perspective of varied populations. At a minimum, training in cultural competence and implicit bias should become part of required ethics education for all IRB members and staff. Finally, IRBs should develop expertise in providing concrete recommendations for investigators in methods and tools to achieve greater diversity (6).

Impediments to inclusion of underrepresented and underserved populations in research are numerous and complex. There are no specific regulatory mandates of the kind that typically drive accountability in clinical research. Institutional commitment to diversity is uneven, the research workforce itself is inadequately diverse, and resistance from the research community to any additional oversight is likely. Further, expertise in the engagement and study of hard-to-reach populations is variable and related infrastructure is limited. Finally, in the United States, some question whether Belmont or the Common Rule are appropriately applied to matters of social justice.

Institutions should support, educate, and resource IRBs, investigators and their study teams, and others in research so that they can give necessary attention to diversity as a fundamental value in the ethical conduct of research. The application of diversity to research review is neither simple nor without risk, but we do not believe the requirement fundamentally differs from other components of IRB review. Overly prescriptive approaches by the IRB and REC, specific mandates, or the application of quotas to study samples will not serve the interests of science and would not be justifiable or palatable to the research community. Drawing attention to diversity and inclusion as a goal and setting reasonable expectations as a condition of study approval, however, will give rise to necessary discussion and collaboration between IRBs and among investigators and the evolution of best practices in the field. Of course, the obligation to promote diversity in clinical research does not rest solely on the IRB or REC or the investigators. Sponsors, regulators, research and academic institutions, funders, patients and patient advocates, and others must build capacity and infrastructure in what, in the end, must be a collaborative enterprise.

As entities that hold investigators accountable, IRBs are themselves accountable to their ethical and regulatory mandates and ultimately to those who serve as participants in research. The duty of IRBs to view subject enrollment and retention beyond the lens of “protection,” to deliberate on the benefits and risks of greater inclusion, and to exercise their authority to promote diversity should be recognized and actively implemented as a matter of justice.

REFERENCES AND NOTES

6. B. E. Bierer et al., “Achieving diversity, inclusion, and equity in clinical research,” version 3.0 (Multi-Regional Clinical Trials Center of Brigham and Women’s Hospital and Harvard, 2020); https://mrcctr.org/diversity-in-clinical-trials/.
11. S. H. Berry et al., “Profile of institutional review board characteristics prior to the 2019 implementation of the revised common rule” (RAND Corporation, 2019); www.rand.org/pubs/research_reports/RR2648.html.

ACKNOWLEDGMENTS

D.H.S. received consulting fees as a member of the Takeda Pharmaceuticals Bioethics Advisory Council.
Justice, diversity, and research ethics review
David H. Strauss, Sarah A. White and Barbara E. Bierer

Science 371 (6535), 1209-1211.
DOI: 10.1126/science.abf2170